Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has
demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to
evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus
anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and
proliferative signaling) in advanced non clear cell renal cell carcinoma.